EUVIMEDEUVIMED entdecken
Open Access

Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc–Biomarkers model

Samuel A P Short, Katherine Wilkinson, Erin Hald, George Howard, Virginia Howard, Suzanne E Judd, Elsayed Z Soliman, Brett Kissela, David Robinson, Robert Stanton, Mary Cushman

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2025.06.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Samuel A P Short und 10 weiteren Autor:innen. Beteiligte Einrichtung: Larner College of Medicine, University of Vermont, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Decision Support Techniques. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anticoagulation reduces ischemic stroke in atrial fibrillation (AF) but increases bleeding. Existing risk calculators guiding anticoagulation decisions in AF have substantial limitations. OBJECTIVES: To determine whether biomarkers of stroke risk for general populations are associated with stroke risk in AF and improve predictive performance of the CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >74, Diabetes, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65-74, Sex category) score. METHODS: The REasons for Geographic And Racial Differences in Stroke (REGARDS) is a prospective cohort study of 30 239 adults enrolled in 2003 to 2007 and monitored for stroke. Participants with AF not taking anticoagulants and with no prior stroke history were studied. Nine circulating biomarkers were measured in stored baseline samples. Cox models, adjusted for demographics and stroke risk factors estimated associations of each biomarker with incident stroke. Then, models with CHA2DS2-VASc score alone or adding biomarkers were compared using tests of fit (likelihood ratio test and Akaike information criterion) and risk discrimination (continuous net reclassification index, [NRI>0]). RESULTS: Among 2411 participants with AF (median age 69 years, 55% female, 36% Black), 163 (7%) developed first-time ischemic stroke over 13 years. Higher N-terminal pro-B-type natriuretic peptide, growth differentiation factor 15, cystatin C, interleukin 6, and lipoprotein (a) were independently associated with higher stroke risk. Biomarkers substantially improved CHA2DS2-VASc model fit (change in Akaike information criterion -13, P 0 0.42). Adding only N-terminal pro-B-type natriuretic peptide and growth differentiation factor 15 yielded the best model fit and a similar NRI>0 compared with all biomarkers. CONCLUSIONS: Five biomarkers were associated with stroke risk in AF, and 2 of these improved CHA2DS2-VASc performance. This improved CHA2DS2-VASc-Biomarkers score can allow better selection of patients for anticoagulation to reduce stroke in AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeDecision Support TechniquesHumansFemaleAgedMaleBiomarkersRisk AssessmentRisk FactorsProspective StudiesMiddle AgedPredictive Value of TestsNatriuretic Peptide, BrainGrowth Differentiation Factor 15United StatesAged, 80 and overAnticoagulantsInterleukin-6Peptide Fragments

Stichwörter der Autor:innen

atrial fibrillationbiomarkerscohort studyischemic strokerisk assessment

Substanzen

BiomarkersNatriuretic Peptide, BrainGrowth Differentiation Factor 15AnticoagulantsGDF15 protein, humanpro-brain natriuretic peptide (1-76)Interleukin-6Peptide Fragments

Autor:innen und Institutionen

  • Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  • Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
  • Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Department of Medicine, the Arctic University of Norway, Trømso, Norway.
  • Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Section on Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Förderung

  • NIGMS NIH HHS
  • NINDS NIH HHS
  • National Institute on Aging
  • NIH National Institute of General Medical Sciences
  • American Heart Association Inc
  • Hemostasis and Thrombosis Research Society
  • National Institutes of Health
  • U.S. Department of Health and Human Services

Zitieren

APA

Short, S. A. P., Wilkinson, K., Hald, E., Howard, G., Howard, V., Judd, S. E., Soliman, E. Z., Kissela, B., Robinson, D., Stanton, R., & Cushman, M. (2025). Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc–Biomarkers model. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.06.007

Vancouver

Short SAP, Wilkinson K, Hald E, Howard G, Howard V, Judd SE, et al. Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc–Biomarkers model. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2025.06.007

BibTeX
@article{Short2025,
  author = {Short, Samuel A P and Wilkinson, Katherine and Hald, Erin and Howard, George and Howard, Virginia and Judd, Suzanne E and Soliman, Elsayed Z and Kissela, Brett and Robinson, David and Stanton, Robert and Cushman, Mary},
  title = {Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc–Biomarkers model},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2025.06.007}
}
Kostenlos starten →